Novartis to invest in next generation therapies to reduce cardiovascular risk

Novartis announced it has entered into a collaboration agreement with Ionis Pharmaceuticals and its its affiliate Akcea Therapeutics. The agreement has been signed to license two novel treatments which reportedly have the potential to reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII. The two antisense therapies developed by Ionis—AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx—have the potential to lower lipoproteins up to 90% and significantly reduce cardiovascular risk in this patient population. In addition, Novartis has signed a stock purchase agreement with Ionis. Ionis’ technology is currently the most effective way to inhibit synthesis of both lipoproteins in the liver, according to data reported in the Lancet. (Source Novartis press release)